Academy of Finland (310011); Tekes (Business Finland) (658/31/2015); Paediatric Research Foundation; Sigrid Jusélius Foundation; Mary och Georg C. Ehrnrooths stiftelse; Laboratoriolääketieteen Edistämissäätiö sr; Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital, Grants No. 9V041, 9X035, and 9AA053. The funding sources played no role in the design or execution of this study or in the analysis and interpretation of the data.
Disclosures: FL was the chief executive and medical officer of Celimmune during the conduct of the study, and today chief scientific officer at Provention Bio. MM is an advisor or consultant for Janssen Research & Development, Dr. Falk Pharma, ImmunogenX, Actobio Therapeutics, Takeda, Jilab, Applied Molecular Transport and Ukko, all outside the submitted work. JI is the chief execute officer of Jilab Inc. that produces diagnostic laboratory services for small-bowel diseases and a wide variety of cancers. JS is an employee of Jilab Inc.
Data series entry GSE145358 for the RNA-Seq data is accepted in GEO.
VD, MO, JI, MM, KV: study concept and design. VD, MO, JT, AP, MP, SS, JS, FL, JI, KV: acquisition of data. VD, MO, MM, JI, KV: analysis and interpretation of data. VD, MO, MM, JI, KV: drafting of the manuscript. All authors were involved in the critical revision of the manuscript for important intellectual content. All authors approved the final version of the manuscript.